Home > Oncology > ASCO 2019 > Gastrointestinal Cancers > KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer

KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer

Presented By
Dr Josep Tabernero, Vall d’Hebron University Hospital, Spain
Conference
ASCO 2019
Trial
Phase 3, KEYNOTE-062
Medical writer: Muriel Cunningham Pembrolizumab plus chemotherapy failed to prolong overall survival (OS) and progression-free survival (PFS) among patients with PD-L1–positive gastric and gastroesophageal cancers, according to results from the phase III KEYNOTE-062 trial (Abstract LBA4007). Pembrolizumab monotherapy improved OS among patients with high PD-L1 expression but not PFS. The objective of the KEYNOTE-062 trial (NCT02494583) was to determine the safety and efficacy of first-line treatment with pembrolizumab with and without chemotherapy in patients with gastric or gastroesophageal cancer. This study was conducted in patients with HER2-negative, advanced gastric or gastroesophageal cancer who had a PD-L1 combined positive score (CPS) of 1 or higher. Josep Tabernero, MD, PhD, of Vall d’Hebron University Hospital, Spain, presented the study results. Patients who met eligibility criteria were randomly selected 1:1:1 to one of the following thre...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on